DE14189577T1 - Behandlung von Blasenentzündung mit hochdosiertem Chondroitinsulfat - Google Patents

Behandlung von Blasenentzündung mit hochdosiertem Chondroitinsulfat Download PDF

Info

Publication number
DE14189577T1
DE14189577T1 DE14189577.1T DE14189577T DE14189577T1 DE 14189577 T1 DE14189577 T1 DE 14189577T1 DE 14189577 T DE14189577 T DE 14189577T DE 14189577 T1 DE14189577 T1 DE 14189577T1
Authority
DE
Germany
Prior art keywords
pharmaceutical composition
chondroitin sulfate
treatment
cystitis
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE14189577.1T
Other languages
English (en)
Other versions
DE14189577T9 (de
Inventor
Peter R. Riehl
Sungtack Samuel Hahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aspire Pharma Ltd
Original Assignee
Aspire Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32850064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE14189577(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aspire Pharma Ltd filed Critical Aspire Pharma Ltd
Publication of DE14189577T1 publication Critical patent/DE14189577T1/de
Application granted granted Critical
Publication of DE14189577T9 publication Critical patent/DE14189577T9/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pharmazeutische Zusammensetzung, ausgelegt zur Einflößung in die Blase eines Patienten, die Zusammensetzung umfassend eine Einheitsdosis Chondroitinsulfat in einer Menge von 350 bis 1200 mg, und einen wässrigen Träger, worin die Chondroitinsulfatkonzentration in der Zusammensetzung von 15 bis 25 mg/mL ist.

Claims (8)

  1. Pharmazeutische Zusammensetzung, ausgelegt zur Einflößung in die Blase eines Patienten, die Zusammensetzung umfassend eine Einheitsdosis Chondroitinsulfat in einer Menge von 350 bis 1200 mg, und einen wässrigen Träger, worin die Chondroitinsulfatkonzentration in der Zusammensetzung von 15 bis 25 mg/mL ist.
  2. Pharmazeutische Zusammensetzung gemäß Anspruch 1, worin die Einheitsdosis Chondroitinsulfat 400 mg ist.
  3. Pharmazeutische Zusammensetzung gemäß irgendeinem vorhergehenden Anspruch, worin die Zusammensetzung eine Chondroitinsulfatkonzentration von 20 mg/mL hat.
  4. Pharmazeutische Zusammensetzung gemäß irgendeinem vorhergehenden Anspruch, bestehend aus 400 mg Chondroitinsulfat und 20 mL eines wässrigen Trägers, worin die pharmazeutische Zusammensetzung steril ist.
  5. Pharmazeutische Zusammensetzung gemäß irgendeinem vorhergehenden Anspruch, worin der wässrige Träger phosphatgepufferte isotonische Kochsalzlösung ist.
  6. Pharmazeutische Zusammensetzung, wie in irgendeinem vorhergehenden Anspruch definiert, zur Verwendung in der Behandlung von interstitieller Cystitis, von GAG-defizienten Formen der Cystitis oder von durch einen chronischen Harnwegsinfekt herbeigeführter GAG-Defizienz, worin die pharmazeutische Zusammensetzung für die Verabreichung durch Einflößung in die Blase eines Patienten ist.
  7. Pharmazeutische Zusammensetzung zur Verwendung gemäß Anspruch 6, worin die Verwendung für die Behandlung von interstitieller Cystitis ist.
  8. Pharmazeutische Zusammensetzung gemäß irgendeinem der Ansprüche 1 bis 5, oder pharmazeutische Zusammensetzung zur Verwendung, wie in Anspruch 6 oder Anspruch 7 beansprucht, worin die pharmazeutische Zusammensetzung frei von Konservierungsmitteln ist.
DE14189577.1T 2003-02-19 2004-02-18 Behandlung von Blasenentzündung mit hochdosiertem Chondroitinsulfat Active DE14189577T9 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US367970 1995-01-03
US10/367,970 US20040161476A1 (en) 2003-02-19 2003-02-19 Cystitis treatment with high dose chondroitin sulfate
EP14189577.1A EP2857024A1 (de) 2003-02-19 2004-02-18 Behandlung von Blasenentzündung mit hochdosiertem Chondroitinsulfat

Publications (2)

Publication Number Publication Date
DE14189577T1 true DE14189577T1 (de) 2019-10-17
DE14189577T9 DE14189577T9 (de) 2020-12-10

Family

ID=32850064

Family Applications (1)

Application Number Title Priority Date Filing Date
DE14189577.1T Active DE14189577T9 (de) 2003-02-19 2004-02-18 Behandlung von Blasenentzündung mit hochdosiertem Chondroitinsulfat

Country Status (15)

Country Link
US (5) US20040161476A1 (de)
EP (2) EP1603578B1 (de)
JP (1) JP4778888B2 (de)
CN (1) CN1758920B (de)
AU (1) AU2004212650B2 (de)
CA (1) CA2515512C (de)
CY (1) CY1116069T1 (de)
DE (1) DE14189577T9 (de)
DK (1) DK1603578T3 (de)
ES (1) ES2527664T3 (de)
HK (2) HK1085136A1 (de)
IL (2) IL170309A (de)
PT (1) PT1603578E (de)
SI (1) SI1603578T1 (de)
WO (1) WO2004073584A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161476A1 (en) * 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
US20070173479A1 (en) * 2003-12-10 2007-07-26 Keryx Biopharmaceuticals, Inc. Methods Using Sulodexide for the Treatment of Bladder Disease
US7414039B2 (en) 2004-01-28 2008-08-19 The Regents Of The University Of California Interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis
ITMI20061030A1 (it) * 2006-05-26 2007-11-27 Altergon Sa Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
US20090023637A1 (en) * 2006-08-30 2009-01-22 Parsons C Lowell Methods for detecting and treating interstitial cystitis
DE102006060953A1 (de) 2006-12-12 2008-08-07 Farco-Pharma Gmbh Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes
US8404655B2 (en) * 2007-05-18 2013-03-26 University Of Florida Research Foundation, Inc. Inhibition of palmitoyl acyl transferase expression and/or activity for the regulation of antiproliferative factor activity
US9849086B2 (en) * 2012-03-19 2017-12-26 Nanologix Research, Inc. Method and composition for treating cystitis
CN107108761B (zh) * 2015-01-09 2020-06-30 生化学工业株式会社 硫酸软骨素衍生物和膀胱疾病处置剂
AU2017326009B2 (en) 2016-09-16 2020-11-12 Glycologix, Inc. Sulfated glycosaminoglycan biomaterials as proteoglycan mimics
DE202017103288U1 (de) 2017-05-12 2018-05-16 Farco-Pharma Gmbh Zusammensetzung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes in Form einer hochdosierten Wirkstoffkombination
ES2769059T3 (es) 2017-05-12 2020-06-24 Farco Gmbh Composición de instilación de la vejiga que contiene sulfato de condonitina (20 mg/ml), ácido hialurónico (16 mg/ml) y buffer de fosfato (pH 6,1 a 7,9) con mayor estabilidad de almacenamiento para el tratamiento de la cistitis
EP3400951B1 (de) 2017-05-12 2019-12-11 Farco-Pharma GmbH Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (4,5 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis
DE202017103289U1 (de) 2017-05-12 2018-05-16 Farco-Pharma Gmbh Zusammensetzung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes in Form einer Wirkstoffkombination
DE202017104675U1 (de) 2017-06-13 2018-06-14 Farco-Pharma Gmbh Zusammensetzung mit lokalanästhetischer Wirkung und deren Verwendung
EP3415163B1 (de) 2017-06-13 2023-02-22 Farco-Pharma GmbH Zusammensetzung mit lokalanästhetischer wirkung und deren verwendung
WO2022246405A1 (en) * 2021-05-18 2022-11-24 Karuna Therapeutics, Inc. Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971955A (en) * 1981-03-02 1990-11-20 Soll David B Protection of human and animal cells during surgical trauma
FR2535324A1 (fr) * 1982-10-27 1984-05-04 Choay Sa Station perfectionnee pour l'epuration d'eaux usees
CA1187798A (en) 1982-03-24 1985-05-28 David B. Soll Protection of cells
AU555747B2 (en) 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
US4886786A (en) * 1985-08-01 1989-12-12 Lindstrom Richard L Additive for irrigation solution or surgical solution
EP0240098A3 (de) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo und Polysaccharide zur Behandlung von Krankheiten verursacht durch Retroviren
IT1213384B (it) * 1986-11-24 1989-12-20 Lab Derivati Organici Mediolan Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare.
US5541166A (en) * 1987-01-23 1996-07-30 The Australian National University Sulphated polysaccharides having anti-metastatic and/or anti-inflammatory activity
US5037810A (en) * 1987-03-17 1991-08-06 Saliba Jr Michael J Medical application for heparin and related molecules
IT1217458B (it) * 1988-05-02 1990-03-22 Crinos Ind Farmacoriologica S Sulfoamino derivati di condroitin solfati,del dermatan solfato e dell' acido ialuronico e loro proprieta' farmacologiche
EP0493533A4 (en) 1989-10-27 1992-10-28 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
CA2020199C (en) 1990-06-29 2002-08-20 Daniel Bar-Shalom Uses of sulphated sugars
DE4021066A1 (de) 1990-07-03 1992-01-09 Hoechst Ag Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden
CA2060223C (en) 1991-02-12 1999-07-20 Clarence C. Lee Injectable medical lubricating fluid composition and method of use
IT1245907B (it) 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
IL102758A (en) 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
CA2100657A1 (en) 1991-11-15 1993-05-16 Glen M. Hartung Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals
AU3905293A (en) 1992-04-17 1993-11-18 Seikagaku Corporation Platinum complex and antineoplastic agent
AU674330B2 (en) 1992-06-30 1996-12-19 Howard K. Shapiro Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
IT1264530B (it) * 1992-07-31 1996-10-02 Crinos Industria Farmaco Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
US6492349B1 (en) * 1993-03-31 2002-12-10 Nutramax Laboratories, Inc. Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue
NZ260933A (en) 1993-07-16 1996-07-26 Hercules Inc Cation-complexed polysaccharides; use in foods and pharmaceuticals
CA2130295A1 (en) 1993-08-26 1995-02-27 Richard A. Berg Ionically crosslinked glycosaminoglycan gels for soft tissue augmentation and drug delivery
WO1995031194A1 (en) 1994-05-11 1995-11-23 Shapiro Howard K Compositions for treatment of chronic inflammatory diseases
IN181358B (de) 1995-02-14 1998-05-30 Bioniche Inc
AUPN261895A0 (en) * 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
CA2232527C (en) * 1995-09-19 2008-09-02 Seikagaku Corporation Anti-inflammatory agent
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
US20030232100A1 (en) * 1998-04-08 2003-12-18 Theoharides Theoharis C. Compositions for treatment of diseases arising from secretion of mast cell biochemicals
CA2269260C (en) 1999-04-16 2002-12-31 Stellar International Inc. Treatment of cystitis with chondroitin sulfate
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
JP2001213784A (ja) * 2000-02-03 2001-08-07 Teisan Seiyaku Kk 乳牛の乳房炎治療剤
EP1311276A4 (de) * 2000-07-31 2007-09-12 Dermal Res Lab Inc Methoden zur prävention oder behandlung von krankheiten und zuständen unter verwendung komplexer kohlenhydrate
ES2374157T3 (es) 2002-10-16 2012-02-14 Arthrodynamic Technologies, Animal Health Division, Inc. Tratamiento para la sinovitis traumática y el cartílago articular dañado.
US7485629B2 (en) * 2002-10-16 2009-02-03 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treatment of joint damage
US7504387B2 (en) * 2002-10-16 2009-03-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate

Also Published As

Publication number Publication date
SI1603578T1 (sl) 2015-04-30
PT1603578E (pt) 2014-12-11
WO2004073584A3 (en) 2005-01-27
US8778908B2 (en) 2014-07-15
US20130143839A1 (en) 2013-06-06
EP2857024A1 (de) 2015-04-08
CN1758920B (zh) 2010-05-26
US20040161476A1 (en) 2004-08-19
US20120058969A1 (en) 2012-03-08
JP2006517928A (ja) 2006-08-03
HK1209037A1 (en) 2016-03-24
DK1603578T3 (en) 2015-01-19
DE14189577T9 (de) 2020-12-10
EP1603578A2 (de) 2005-12-14
US7772210B2 (en) 2010-08-10
IL170309A (en) 2015-11-30
AU2004212650A1 (en) 2004-09-02
ES2527664T3 (es) 2015-01-28
IL238811A (en) 2017-03-30
JP4778888B2 (ja) 2011-09-21
US8334276B2 (en) 2012-12-18
WO2004073584A2 (en) 2004-09-02
HK1085136A1 (en) 2006-08-18
EP1603578B1 (de) 2014-10-29
US20060194757A1 (en) 2006-08-31
IL238811A0 (en) 2015-06-30
US20100292182A1 (en) 2010-11-18
CN1758920A (zh) 2006-04-12
US8084441B2 (en) 2011-12-27
CA2515512C (en) 2012-07-10
CA2515512A1 (en) 2004-09-02
AU2004212650B2 (en) 2009-07-23
CY1116069T1 (el) 2017-02-08

Similar Documents

Publication Publication Date Title
DE14189577T1 (de) Behandlung von Blasenentzündung mit hochdosiertem Chondroitinsulfat
DE236684T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE602006020070D1 (de) Verringerung von schwindel, einer nebenwirkung im zusammenhang mit einer pirfenidon-therapie
BRPI0516024A (pt) uso de azd 2171 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
HK1119071A1 (en) Combinations of therapeutic agents
HUP0102489A2 (hu) Biokémiai anyagok alkalmazása emberi test szerveiben található simaizomsejtek összehúzódása okozta egészségi állapotok megelőzésére és kezelésére alkalmas készítményekben
BR0213906A (pt) Métodos para a produção de um efeito anti-angiogênico e ou redutor da permeabilidade vascular em um animal de sangue quente, e para o tratamento de um câncer em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6474 ou um seu sal farmaceuticamente aceitável e um taxano
BR0313117A (pt) Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável
DE502006002773D1 (de) Verwendung von Pelargonium Extrakten in Kombination mit Plantago zur Herstellung eines Medikaments zur Behandlung der Rachenentzündung
BRPI0519022A2 (pt) formaÇço insitu de implante para animais
CN101112381A (zh) 一种关节腔内注射用药物组合物
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
CN103948661A (zh) 用于治疗妇科疾病、前列腺疾病或肛肠疾病的药物组合物及其应用
He et al. [Retracted] Clinical Effect of Microneedle Injection Combined with Blood Transfusion in the Treatment of Severe Anemia Complicated with Vitiligo under Regenerative Medical Technology
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
RU2006119263A (ru) Способ лечения больных розацеа
RU2003113987A (ru) Способ лечения и профилактики заболеваний воздействием на биологически активные точки и зоны
Singh et al. Assessment of efficacy of Platelet rich plasma therapy for acne scars
CN2827391Y (zh) 胰岛素注射部位定位板
HK1042238A1 (en) Treatment of symptoms of parkinson's disease with an agent comprising a dopaminergic substance and a local anaesthetic of the anilide group
Chaudhary et al. Honey ‘The Life Saviour’in Necrotising Fascitis: A Case Report
Hughes HBOT: An Essential Component for the Regenerative Treatment of Pain from Sports Injuries, Chronic Inflammation and Infection
Shi et al. Trichloropropane and dichlorohydrin associated with painful peripheral neurotoxicity
CN2696662Y (zh) 一种术后切口敷贴
Melnik et al. Pharmacological research of the dental gel with carbon dioxide Humulus lupulus extract